Taiho and Cullinan Celebrate Phase 3 Victory for Lung Cancer Drug Zipalertinib
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung cancer niche.
The findings position their drug, zipalertinib, as a strong contender in the ongoing lung cancer drug battle.
TaihoCullinanJohnson & Johnson
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — New Taiho, Cullian data heats up lung cancer drug battle“Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung”
fierce biotech — <a href="/biotech/cullinan-tees-jj-fight-and-100m-payday-taiho-partnered-drug-hits-cancer-goal" hreflang="en">Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal</a>